Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Adriablastin
2. Adriablastine
3. Adriamycin
4. Adriblastin
5. Adriblastina
6. Adriblastine
7. Adrimedac
8. Doxo Cell
9. Doxo-cell
10. Doxolem
11. Doxorubicin
12. Doxorubicin Hexal
13. Doxorubicin Nc
14. Doxorubicina Ferrer Farm
15. Doxorubicina Funk
16. Doxorubicina Tedec
17. Doxorubicine Baxter
18. Doxotec
19. Farmiblastina
20. Hydrochloride, Doxorubicin
21. Myocet
22. Onkodox
23. Ribodoxo
24. Rubex
25. Urokit Doxo Cell
26. Urokit Doxo-cell
1. 25316-40-9
2. Doxorubicin Hcl
3. Rubex
4. Adriacin
5. Adriblastina
6. Caelyx
7. Doxil
8. Adriamycin Hydrochloride
9. Doxorubicin (adriamycin) Hcl
10. Adriamycin, Hydrochloride
11. Doxorubicin (hydrochloride)
12. Hydroxydaunorubicin Hydrochloride
13. Adriablastina Cs
14. Adriblastin
15. Nsc 123127
16. Hydroxydaunomycin Hydrochloride
17. Mls001401460
18. 82f2g7bl4e
19. Adm Hydrochloride
20. Lipodox
21. Smr000058570
22. Adriamycin Pfs
23. Adriamycin Rdf
24. Dsstox_cid_10636
25. Dsstox_rid_78854
26. Dsstox_rid_80678
27. Dsstox_gsid_30636
28. Dsstox_gsid_45111
29. (8s,10s)-10-(((2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione Hydrochloride
30. (8s,10s)-10-{[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione Hydrochloride
31. Adrosal
32. Duxocin
33. Doxorubicin Citric Acid Salt
34. Adriamycin Hydrochloride-dna Complex
35. Mls000028393
36. Mfcd00077757
37. Lipo-dox
38. Fi 6804
39. (7s,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride
40. (8s-cis)-10-[(3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxynaphthacene-5,12-dione Hydrochloride
41. Nsc-123127
42. Sr-01000003049
43. Kw-125
44. Unii-82f2g7bl4e
45. Resmycin
46. Ccris 740
47. Doxorubicin.hcl
48. Doxorubicin Hydrochloride [jan]
49. Doxorubicin, Hcl
50. Adriamycin (tn)
51. Adriacin (tn)
52. (1s,3s)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-l-lyxo-hexopyranoside Hydrochloride
53. (8s,10s)-10-((2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyltetrahydro-2h-pyran-2-yloxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione Hydrochloride
54. (8s-cis)-10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxynaphthacene-5,12-dione Hydrochloride
55. Prestwick_188
56. Einecs 246-818-3
57. Doxorubicin Hydrochloride [usp:jan]
58. Doxil (tn)
59. Rubex (tn)
60. Cpd000058570
61. Adriblastina Hydrochloride
62. (8s,10s)-10-(((2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracen
63. Dox
64. Adriamycin [iarc]
65. Doxorubicini Hydrochloridum
66. Ncgc00163543-01
67. Schembl3242
68. Cas-25316-40-9
69. Mls000049969
70. Mls000049970
71. Mls000049971
72. Mls000070047
73. Mls000392861
74. Mls000392871
75. Mls000392881
76. Mls000392891
77. Mls000392901
78. Mls000759533
79. Mls001055359
80. Doxorubicin Hydrochloride,(s)
81. Chembl359744
82. Dtxsid3030636
83. Chebi:31522
84. Doxorubicin Hydrochloride- Bio-x
85. Doxorubicin Hydrochloride Solution
86. Liposomal Doxorubicin Hydrochloride
87. Bcpp000429
88. Hms1569g18
89. Kuc110341c
90. Ex-a1337
91. Tox21_110050
92. Tox21_112061
93. Tox21_202483
94. Adriamycin (doxorubicin Hydrochloride
95. S1208
96. Akos007930231
97. Akos015920241
98. Doxorubicin Hydrochloride (jp17/usp)
99. Tox21_110050_1
100. Bcp9000237
101. Ccg-100975
102. Cs-1239
103. Nc00225
104. 2-chloro-4-fluorobenzenesulphonylchloride
105. Doxorubicin Hydrochloride [mart.]
106. Doxorubicin Hydrochloride [vandf]
107. Doxorubicin Hydrochloride Liposome
108. Ncgc00014486-01
109. Ncgc00024415-33
110. Ncgc00024415-36
111. Ncgc00260032-01
112. Ncgc00263918-03
113. (8s,10s)-10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione Hydrochloride
114. As-31687
115. Bd164391
116. Doxorubicin Hydrochloride [usp-rs]
117. Doxorubicin Hydrochloride [who-dd]
118. Doxorubicin Hydrochloride [who-ip]
119. Hy-15142
120. Ksc-230-184-1
121. Doxorubicin Hydrochloride [ema Epar]
122. D01275
123. Doxorubicin Hydrochloride [ep Monograph]
124. Doxorubicin Hydrochloride [orange Book]
125. Doxorubicin Hydrochloride [usp Monograph]
126. 316d409
127. A817779
128. Doxorubicin Hydrochloride Liposome [vandf]
129. Doxorubicin Liposomal Complex Of The Hydrochloride
130. Doxorubicini Hydrochloridum [who-ip Latin]
131. Doxorubicin Hydrochloride, 98.0-102.0% (hplc)
132. Imx-110 Component Doxorubicin Hydrochloride
133. Liposomal Doxorubicin Hydrochloride [who-dd]
134. Sr-01000003049-5
135. Q27032359
136. Sr-01000003049-10
137. Z1557399790
138. Doxorubicin Liposomal Complex Of The Hydrochloride [mi]
139. Doxorubicin Hydrochloride, European Pharmacopoeia (ep) Reference Standard
140. Doxorubicin Hydrochloride, Suitable For Fluorescence, 98.0-102.0% (hplc)
141. Doxorubicin Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
142. Doxorubicin Hydrochloride, United States Pharmacopeia (usp) Reference Standard
143. (8s,10s)-10-(((2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dionehydrochloride
144. (8s,10s)-10-((3-amino-2,3,6-trideoxy-.alpha.-l-lyxo-hexopyranosyl)oxy)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione Hydrochloride
145. 10-[(3-amino-2,3,6-trideoxy-?-l-lyxohexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-5,12-naphthacenedione Hydrochloride
146. 5,12-naphthacenedione, 10-((3-amino-2,3,6-trideoxy-.alpha.-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxylacetyl)-1-methoxy-, Hydrochloride (8s-cis)-
147. 5,12-naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, Hydrochloride, (8s,10s)-
148. 5,12-naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, Hydrochloride, (8s-cis)-
149. 5,12-naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxylacetyl)-1-methoxy-, Hydrochloride (8s-cis)-
| Molecular Weight | 580.0 g/mol |
|---|---|
| Molecular Formula | C27H30ClNO11 |
| Hydrogen Bond Donor Count | 7 |
| Hydrogen Bond Acceptor Count | 12 |
| Rotatable Bond Count | 5 |
| Exact Mass | 579.1507385 g/mol |
| Monoisotopic Mass | 579.1507385 g/mol |
| Topological Polar Surface Area | 206 Ų |
| Heavy Atom Count | 40 |
| Formal Charge | 0 |
| Complexity | 977 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Doxorubicin hydrochloride |
| PubMed Health | Doxorubicin Hydrochloride Liposome (Injection) |
| Drug Classes | Antineoplastic Agent |
| Drug Label | Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin consists of a naphthacenequinone nucleus linked through a glycosidic bond at ring atom 7 to an amino sugar, daunosamine. Ch... |
| Active Ingredient | Doxorubicin hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 2mg/ml; 10mg/vial; 200mg/100ml; 50mg/vial; 20mg/vial |
| Market Status | Prescription |
| Company | Fresenius Kabi Usa; Pharmachemie Bv; Onco Therapies; Sun Pharm Inds; Teva Pharms Usa; Sagent Pharms; Eurohlth Intl; Alvogen; Sandoz; Actavis |
| 2 of 2 | |
|---|---|
| Drug Name | Doxorubicin hydrochloride |
| PubMed Health | Doxorubicin Hydrochloride Liposome (Injection) |
| Drug Classes | Antineoplastic Agent |
| Drug Label | Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin consists of a naphthacenequinone nucleus linked through a glycosidic bond at ring atom 7 to an amino sugar, daunosamine. Ch... |
| Active Ingredient | Doxorubicin hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 2mg/ml; 10mg/vial; 200mg/100ml; 50mg/vial; 20mg/vial |
| Market Status | Prescription |
| Company | Fresenius Kabi Usa; Pharmachemie Bv; Onco Therapies; Sun Pharm Inds; Teva Pharms Usa; Sagent Pharms; Eurohlth Intl; Alvogen; Sandoz; Actavis |
Myocet liposomal, in combination with cyclophosphamide, is indicated for the first-line treatment of metastatic breast cancer in adult women.
Caelyx pegylated liposomal is indicated:
- as monotherapy for patients with metastatic breast cancer , where there is an increased cardiac risk;
- for treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen;
- in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant;
- for treatment of AIDS-related Kaposis sarcoma (KS) in patients with low CD4 counts (< 200 CD4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease.
Caelyx pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standarddoxorubicin (or other anthracycline).
Treatment of breast and ovarian cancer .
Treatment of hepatocellular carcinoma
Topoisomerase II Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)
Antibiotics, Antineoplastic
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)
L01DB01
L01DB
L01DB01
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - INJECTABLE;INJECTION - 150MG/75ML
USFDA APPLICATION NUMBER - 50629
DOSAGE - INJECTABLE;INJECTION - 200MG/100ML
USFDA APPLICATION NUMBER - 50629
DOSAGE - INJECTABLE;INJECTION - 2MG/ML
USFDA APPLICATION NUMBER - 50629
DOSAGE - INJECTABLE, LIPOSOMAL;INJECTION - 20...DOSAGE - INJECTABLE, LIPOSOMAL;INJECTION - 20MG/10ML (2MG/ML)
USFDA APPLICATION NUMBER - 50718
DOSAGE - INJECTABLE, LIPOSOMAL;INJECTION - 50...DOSAGE - INJECTABLE, LIPOSOMAL;INJECTION - 50MG/25ML (2MG/ML)
USFDA APPLICATION NUMBER - 50718
Related Excipient Companies
Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Minbiotech
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nippon Fine Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Parenteral
Granulation
Co-Processed Excipients
Direct Compression
Taste Masking
Coating Systems & Additives
Surfactant & Foaming Agents
Solubilizers
Emulsifying Agents
Thickeners and Stabilizers
Topical
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
37
PharmaCompass offers a list of Doxorubicin Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Doxorubicin Hydrochloride manufacturer or Doxorubicin Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Doxorubicin Hydrochloride manufacturer or Doxorubicin Hydrochloride supplier.
PharmaCompass also assists you with knowing the Doxorubicin Hydrochloride API Price utilized in the formulation of products. Doxorubicin Hydrochloride API Price is not always fixed or binding as the Doxorubicin Hydrochloride Price is obtained through a variety of data sources. The Doxorubicin Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Adriblastine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Adriblastine, including repackagers and relabelers. The FDA regulates Adriblastine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Adriblastine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Adriblastine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Adriblastine supplier is an individual or a company that provides Adriblastine active pharmaceutical ingredient (API) or Adriblastine finished formulations upon request. The Adriblastine suppliers may include Adriblastine API manufacturers, exporters, distributors and traders.
click here to find a list of Adriblastine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Adriblastine DMF (Drug Master File) is a document detailing the whole manufacturing process of Adriblastine active pharmaceutical ingredient (API) in detail. Different forms of Adriblastine DMFs exist exist since differing nations have different regulations, such as Adriblastine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Adriblastine DMF submitted to regulatory agencies in the US is known as a USDMF. Adriblastine USDMF includes data on Adriblastine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Adriblastine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Adriblastine suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Adriblastine Drug Master File in Japan (Adriblastine JDMF) empowers Adriblastine API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Adriblastine JDMF during the approval evaluation for pharmaceutical products. At the time of Adriblastine JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Adriblastine suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Adriblastine Drug Master File in Korea (Adriblastine KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Adriblastine. The MFDS reviews the Adriblastine KDMF as part of the drug registration process and uses the information provided in the Adriblastine KDMF to evaluate the safety and efficacy of the drug.
After submitting a Adriblastine KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Adriblastine API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Adriblastine suppliers with KDMF on PharmaCompass.
A Adriblastine CEP of the European Pharmacopoeia monograph is often referred to as a Adriblastine Certificate of Suitability (COS). The purpose of a Adriblastine CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Adriblastine EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Adriblastine to their clients by showing that a Adriblastine CEP has been issued for it. The manufacturer submits a Adriblastine CEP (COS) as part of the market authorization procedure, and it takes on the role of a Adriblastine CEP holder for the record. Additionally, the data presented in the Adriblastine CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Adriblastine DMF.
A Adriblastine CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Adriblastine CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Adriblastine suppliers with CEP (COS) on PharmaCompass.
A Adriblastine written confirmation (Adriblastine WC) is an official document issued by a regulatory agency to a Adriblastine manufacturer, verifying that the manufacturing facility of a Adriblastine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Adriblastine APIs or Adriblastine finished pharmaceutical products to another nation, regulatory agencies frequently require a Adriblastine WC (written confirmation) as part of the regulatory process.
click here to find a list of Adriblastine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Adriblastine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Adriblastine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Adriblastine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Adriblastine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Adriblastine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Adriblastine suppliers with NDC on PharmaCompass.
Adriblastine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Adriblastine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Adriblastine GMP manufacturer or Adriblastine GMP API supplier for your needs.
A Adriblastine CoA (Certificate of Analysis) is a formal document that attests to Adriblastine's compliance with Adriblastine specifications and serves as a tool for batch-level quality control.
Adriblastine CoA mostly includes findings from lab analyses of a specific batch. For each Adriblastine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Adriblastine may be tested according to a variety of international standards, such as European Pharmacopoeia (Adriblastine EP), Adriblastine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Adriblastine USP).
